Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).

Leighl NB, Redman MW, Rizvi N, Hirsch FR, Mack PC, Schwartz LH, Wade JL, Irvin WJ, Reddy SC, Crawford J, Bradley JD, Stinchcombe TE, Ramalingam SS, Miao J, Minichiello K, Herbst RS, Papadimitrakopoulou VA, Kelly K, Gandara DR

Open source

DOI: 10.1136/jitc-2021-002973
Published: 2021 Aug
Container: Journal for immunotherapy of cancer
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/jitc-2021-002973,
  title = {Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).},
  author = {Leighl NB and Redman MW and Rizvi N and Hirsch FR and Mack PC and Schwartz LH and Wade JL and Irvin WJ and Reddy SC and Crawford J and Bradley JD and Stinchcombe TE and Ramalingam SS and Miao J and Minichiello K and Herbst RS and Papadimitrakopoulou VA and Kelly K and Gandara DR},
  year = {2021},
  journal = {Journal for immunotherapy of cancer},
  doi = {10.1136/jitc-2021-002973},
  url = {https://doi.org/10.1136/jitc-2021-002973}
}

RIS

TY  - JOUR
TI  - Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
AU  - Leighl NB
AU  - Redman MW
AU  - Rizvi N
AU  - Hirsch FR
AU  - Mack PC
AU  - Schwartz LH
AU  - Wade JL
AU  - Irvin WJ
AU  - Reddy SC
AU  - Crawford J
AU  - Bradley JD
AU  - Stinchcombe TE
AU  - Ramalingam SS
AU  - Miao J
AU  - Minichiello K
AU  - Herbst RS
AU  - Papadimitrakopoulou VA
AU  - Kelly K
AU  - Gandara DR
PY  - 2021
JO  - Journal for immunotherapy of cancer
DO  - 10.1136/jitc-2021-002973
UR  - https://doi.org/10.1136/jitc-2021-002973
ER  -

APA

NB, L., MW, R., N, R., FR, H., PC, M., LH, S., JL, W., WJ, I., SC, R., J, C., JD, B., TE, S., SS, R., J, M., K, M., RS, H., VA, P., K, K., & DR, G. (2021). Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).. Journal for immunotherapy of cancer. https://doi.org/10.1136/jitc-2021-002973

Source records

pubmed · retrieved 2026-09-26T10:59:53.572Z
europe-pmc · retrieved 2026-09-26T10:59:53.584Z
doaj · retrieved 2026-09-26T10:59:53.572Z